Tonix Pharmaceuticals Holding Corp. announced a new managed Medicare payer agreement for its fibromyalgia treatment TONMYA, effective immediately. This addition covers approximately 21 million beneficiaries, bringing total Medicare coverage to 32 million lives (58% of U.S. Medicare). Combined with commercial and government payers, total coverage now reaches approximately 166 million individuals (53% of the U.S. population). The company also reported that its sales force has expanded to 150 representatives following the activation of 50 new hires. Tonix Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system disorders, infectious diseases, and immunology conditions.
